Dramatic expansion of biomedical data in the post-genomic era on various organisms, including humans, has disclosed the enormous complexity of biological systems and increased our knowledge of many disease processes. This is particularly evident in reference to neoplastic disorders where molecular technologies on a genome, epigenome, transcriptome and proteomic scale have disclosed unique molecular pathways and their networks that provide significant information concerning therapeutic strategies and clinical outcomes. This in turn has affected the standard of practice of many medical disciplines including pathology. The newly developed concept of personalized and targeted therapies in cancer medicine increased and changed the traditional roles of pathology as a clinical discipline. The expanding molecular testing of tumors, with complex technologic approaches, requires a redesign of the conventional microscopic pathology services. This T32 proposal is intended to provide resources to train a new generation of pathologists via laboratory-based research training that will complement the current Accreditation Council for Graduate Medical Education-accredited clinical fellowship programs of the Department of Pathology at The University of Texas MD Anderson Cancer Center. The goal of this program is to train the next generation of physician/scientist pathologists capable of combining the conventional role of diagnostic pathology with investigative molecular approaches. To accomplish this goal, a focused 2-year research program will pair trainees with experienced educators who are also accomplished translational researchers. The trainees will work in their mentors'laboratories training in laboratory methods, processes, and team orientation needed in today's translational research. The graduates of this program will complete research projects aimed at improving patient care with patient-directed personalized treatment, concluding with the submission of a manuscript to a peer-reviewed journal. Coursework and a wide range of educational opportunities at The University of Texas MD Anderson Cancer Center will complement the laboratory research training. Combined with subspecialty clinical training, this program will produce extremely well-qualified academic, research-oriented pathologists who can, by themselves, be independent researchers and future academic mentors.

Public Health Relevance

This research training program is especially relevant to Public Health as evolving cancer treatment modalities moves into molecularly targeted and individualized therapies. Therefore, well-trained molecular pathologists who have proven diagnostic skills coupled with laboratory- based research training will be critical in delivering te contemporary cancer care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA163185-02
Application #
8337748
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
2011-09-23
Project End
2016-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
2
Fiscal Year
2012
Total Cost
$438,857
Indirect Cost
$29,423
Name
University of Texas MD Anderson Cancer Center
Department
Pathology
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Olar, Adriana; Goodman, Lindsey D; Wani, Khalida M et al. (2018) A gene expression signature predicts recurrence-free survival in meningioma. Oncotarget 9:16087-16098
Chen, Xian; Low, Kwang-Huei; Alexander, Angela et al. (2018) Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clin Cancer Res 24:6594-6610
Capper, David; Jones, David T W; Sill, Martin et al. (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469-474
Doostan, Iman; Karakas, Cansu; Kohansal, Mehrnoosh et al. (2017) Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clin Cancer Res 23:7288-7300
Olar, Adriana; Wani, Khalida M; Wilson, Charmaine D et al. (2017) Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol 133:431-444
Sans, Marta; Gharpure, Kshipra; Tibshirani, Robert et al. (2017) Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Res 77:2903-2913
Roh, Whijae; Chen, Pei-Ling; Reuben, Alexandre et al. (2017) Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9:
Reuben, Alexandre; Spencer, Christine N; Prieto, Peter A et al. (2017) Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2:
Kim, Dae Won; Haydu, Lauren E; Joon, Aron Y et al. (2017) Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer 123:1372-1381
Dadhania, Vipulkumar; Zhang, Miao; Zhang, Li et al. (2016) Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine 12:105-117

Showing the most recent 10 out of 46 publications